Capital Requirements, Liquidity and Going Concern Considerations	9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Capital Requirements, Liquidity and Going Concern Considerations	Note 3 – Capital Requirements, Liquidity and Going Concern Considerations The Company had positive working capital of approximately $8.2 million at September 30, 2021 and a deficiency in working capital of $1.2 million at December 31, 2020. The Company had a net loss of approximately $5.7 million for the nine months ended September 30, 2021, and used cash in operations of approximately $5.7 million at September 30, 2021. The Company expects to continue to incur significant expenditures to develop and expand its owned and managed outpatient medical clinics. Prior to the Company’s March 2021 public offering, the Company funded its business plan through debt and equity securities. During the quarter ended March 31, 2021, the Company completed a public offering and received proceeds of approximately $17 million. During the quarter ended June 30, 2021, the Company sold an additional 1,193,750 shares for proceeds of approximately $1.9 million. These events served to mitigate the conditions that historically raised substantial doubt about the Company’s ability to continue as a going concern. Based on the proceeds received, the Company has the ability to continue as a going concern for at least the next 12 months and meet its financial obligations as they become due.

Capital Requirements, Liquidity and Going Concern Considerations

9 Months Ended

Sep. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Capital Requirements, Liquidity and Going Concern Considerations

Note 3 – Capital Requirements, Liquidity and Going Concern Considerations

The Company had positive working capital of approximately $8.2 million at September 30, 2021 and a deficiency in working capital of $1.2 million at December 31, 2020. The Company had a net loss of approximately $5.7 million for the nine months ended September 30, 2021, and used cash in operations of approximately $5.7 million at September 30, 2021. The Company expects to continue to incur significant expenditures to develop and expand its owned and managed outpatient medical clinics.

Prior to the Company’s March 2021 public offering, the Company funded its business plan through debt and equity securities. During the quarter ended March 31, 2021, the Company completed a public offering and received proceeds of approximately $17 million. During the quarter ended June 30, 2021, the Company sold an additional 1,193,750 shares for proceeds of approximately $1.9 million. These events served to mitigate the conditions that historically raised substantial doubt about the Company’s ability to continue as a going concern.

Based on the proceeds received, the Company has the ability to continue as a going concern for at least the next 12 months and meet its financial obligations as they become due.